DUBLIN--(BUSINESS WIRE)--The "Generalized Tonic-Clonic Seizure Ongoing Global Clinical Trials Analysis and Outlook" report has been added to ResearchAndMarkets.com's offering. Generalized Tonic-Clonic ...
-- New approval for VIMPAT® (lacosamide) CV in the U.S. as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures (PGTCS) in patients four years of age and older -- All three ...
February 4, 2010 — The US Food and Drug Administration (FDA) has approved an expanded indication for lamotrigine extended-release tablets (Lamictal XR, GlaxoSmithKline) as once-daily adjunctive ...
FINTEPLA is approved by the U.S. Food and Drug Administration (FDA) for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients two years of age and older 1 ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. DENVER — Primary generalized tonic-clonic seizures ...
LONDON--(BUSINESS WIRE)-- LivaNova PLC (LIVN), a market-leading medical technology company, today announced that 24-month data on generalized tonic-clonic (GTC) seizures in people with drug-resistant ...
-- Submission supported by positive preliminary 18-month NAUTILUS data in patients with drug-resistant idiopathic generalized epilepsy (IGE) and generalized tonic-clonic (GTC) seizures -- The PMA-S is ...
WASHINGTON -- Technologies to provide instant at-home detection of life-threatening seizures and that could allow epilepsy patients to monitor their own drug levels are on the horizon, researchers ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The study included 426 women with IGE or tonic-clonic ...
Eisai announced results from a Phase 3 Study 332 trial of perampanel, an AMPA receptor antagonist in patients with primary generalized tonic-clonic (PGTC) seizures. Study 332 was a double-blind, ...
ATLANTA, June 24, 2024 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced that Epilepsia published findings from a comprehensive scoping review examining the efficacy of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results